Clarus Therapeutics To Present Phase 3 Data For REXTORO® At ICE/ENDO 2014
5/28/2014 9:14:18 AM
NORTHBROOK, Ill., May 28, 2014 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the development and commercialization of REXTORO, an oral testosterone (T) replacement product, today announced the presentation of two posters at the 16th International Congress of Endocrinology and The Endocrine Society's 96th Annual Meeting and Expo, June 21-24 in Chicago. This will be the first time in almost 20 years the two groups will unite to present ICE/ENDO 2014, with over 10,000 endocrinologists and hormone researchers from around the world expected to attend.
Help employers find you! Check out all the jobs and post your resume.
comments powered by